Keynote 867
The purpose of this study is to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) plus pembrolizumab (MK-3475) in the treatment of adult participants with unresected stage I or II (Stage IIB N0, M0) non-small cell lung cancer (NSCLC).
The primary study hypotheses are:
CLINICALTRIALS.GOV IDENTIFIER:
NCT03924869
When speaking to your doctor, please have the trial identifier number available.
All patients who enrol in the trial will receive treatment while on the study. You will have an equal chance of receiving one of the following treatments:
50% will receive SBRT and pembrolizumab
50% will receive SBRT and placebo
*Neither you nor the study doctor will know what you are getting. In case of a health emergency, the study doctor can get this information.
Tests the medicine or vaccine in large groups of trial participants (from several hundred to several thousand). For medicines, volunteers have the disease or condition the medicine is designed to treat. In vaccine studies, the volunteers may be healthy or have diseases or conditions. Phase 3 trials take place in hospitals, clinics, or physician offices.
Dates
Only a qualified healthcare professional can determine your eligibility. However, this information may be useful in starting a conversation with your doctor.
Conditions
Non-Small Cell Lung Cancer
Age Range
18 - No Age Maximum
Sex
All
Locations provided may not reflect the most current site information. Please call the number provided in the location results to confirm.
Print this page
Email this page